LY-487,379

Chemical compound
  • none
Identifiers
  • N-(4-(2-methoxyphenoxy)phenyl)- N-(2,2,2-trifluoroethylsulfonyl)pyrid- 3-ylmethylamine
CAS Number
  • 353231-17-1 checkY
PubChem CID
  • 9825084
IUPHAR/BPS
  • 1402
ChemSpider
  • 8000831 ☒N
UNII
  • 7WF5ZLL4D9
ChEMBL
  • ChEMBL108939 ☒N
CompTox Dashboard (EPA)
  • DTXSID10431366 Edit this at Wikidata
Chemical and physical dataFormulaC21H19F3N2O4SMolar mass452.45 g·mol−13D model (JSmol)
  • Interactive image
  • c3ncccc3CN(S(=O)(=O)CC(F)(F)F)c2ccc(cc2)Oc1ccccc1OC
InChI
  • InChI=1S/C21H19F3N2O4S/c1-29-19-6-2-3-7-20(19)30-18-10-8-17(9-11-18)26(14-16-5-4-12-25-13-16)31(27,28)15-21(22,23)24/h2-13H,14-15H2,1H3 ☒N
  • Key:ALMACYDZFBMGOR-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

LY-487,379 is a drug used in scientific research that acts as a selective positive allosteric modulator for the metabotropic glutamate receptor group II subtype mGluR2.[1] It is used to study the structure and function of this receptor subtype,[2][3] and LY-487,379 along with various other mGluR2/3 agonists and positive modulators are being investigated as possible antipsychotic and anxiolytic drugs.[4][5][6][7][8]

See also

  • Eglumegad
  • HYDIA

References

  1. ^ Johnson MP, Baez M, Jagdmann GE, Britton TC, Large TH, Callagaro DO, et al. (July 2003). "Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine". Journal of Medicinal Chemistry. 46 (15): 3189–92. doi:10.1021/jm034015u. PMID 12852748.
  2. ^ Schaffhauser H, Rowe BA, Morales S, Chavez-Noriega LE, Yin R, Jachec C, et al. (October 2003). "Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2". Molecular Pharmacology. 64 (4): 798–810. doi:10.1124/mol.64.4.798. PMID 14500736. S2CID 15919973.
  3. ^ Poisik O, Raju DV, Verreault M, Rodriguez A, Abeniyi OA, Conn PJ, Smith Y (2005). "Metabotropic glutamate receptor 2 modulates excitatory synaptic transmission in the rat globus pallidus". Neuropharmacology. 49 (Suppl 1): 57–69. doi:10.1016/j.neuropharm.2005.03.006. PMID 15993439. S2CID 21881395.
  4. ^ Galici R, Echemendia NG, Rodriguez AL, Conn PJ (December 2005). "A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity" (PDF). The Journal of Pharmacology and Experimental Therapeutics. 315 (3): 1181–1187. doi:10.1124/jpet.105.091074. PMID 16123306. S2CID 9159875. Archived from the original (PDF) on 2019-02-21.
  5. ^ Marino MJ, Conn PJ (February 2006). "Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors". Current Opinion in Pharmacology. 6 (1): 98–102. doi:10.1016/j.coph.2005.09.006. PMID 16368268.
  6. ^ Harich S, Gross G, Bespalov A (July 2007). "Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment". Psychopharmacology. 192 (4): 511–9. doi:10.1007/s00213-007-0742-y. PMID 17318501. S2CID 7551116.
  7. ^ Conn PJ, Jones CK (January 2009). "Promise of mGluR2/3 activators in psychiatry". Neuropsychopharmacology. 34 (1): 248–9. doi:10.1038/npp.2008.156. PMC 2907744. PMID 19079073.
  8. ^ Hermes ML, Renaud LP (March 2011). "Postsynaptic and presynaptic group II metabotropic glutamate receptor activation reduces neuronal excitability in rat midline paraventricular thalamic nucleus" (PDF). The Journal of Pharmacology and Experimental Therapeutics. 336 (3): 840–9. doi:10.1124/jpet.110.176149. PMID 21139059. S2CID 25111011. Archived from the original (PDF) on 2019-02-22.
  • v
  • t
  • e
Metabotropic glutamate receptor modulators
Group I
mGluR1Tooltip Metabotropic glutamate receptor 1
mGluR5Tooltip Metabotropic glutamate receptor 5
Group II
mGluR2Tooltip Metabotropic glutamate receptor 2
mGluR3Tooltip Metabotropic glutamate receptor 3
Group III
mGluR4Tooltip Metabotropic glutamate receptor 4
  • Antagonists: CPPG
  • MAP4
  • MPPG
  • MSOP
  • MTPG
  • UBP-1112
mGluR6Tooltip Metabotropic glutamate receptor 6
  • Antagonists: CPPG
  • MAP4
  • MPPG
  • MSOP
  • MTPG
  • UBP-1112
mGluR7Tooltip Metabotropic glutamate receptor 7
  • Antagonists: CPPG
  • MAP4
  • MMPIP
  • MPPG
  • MSOP
  • MTPG
  • UBP-1112
  • XAP044; Negative allosteric modulators: ADX71743
mGluR8Tooltip Metabotropic glutamate receptor 8
  • Antagonists: CPPG
  • MAP4
  • MPPG
  • MSOP
  • MTPG
  • UBP-1112
See also: Receptor/signaling modulators • Ionotropic glutamate receptor modulators • Glutamate metabolism/transport modulators
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e